Predicting Brain Amyloid Accumulation Using RetiSpec

Ontario Industry Updates
Written By Doriane Rey

RetiSpec is excited to share its latest clinical study findings including a video and insights from lead author Sharon Cohen, MD, FRCPC, neurologist and assistant professor at the University of Toronto.

Dr. Cohen discussed data presented in November 2021 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD) on RetiSpec, a retinal imaging tool that predicts brain amyloid status.

RetiSpec, a noninvasive retinal imaging tool, uses hyperspectral technology combined with artificial intelligence to look for distinctive signs of Alzheimer disease (AD), as well as Parkinson disease, vascular dementia, and amyotrophic lateral sclerosis.

RetiSpec is an OBIO® BDSP™ company and presented at a past OBIO Investment Summit.

Doriane Rey
Previous

OPTT, a presenting company at the 2022 OBIO Investment Summit, selected for Morgan Stanley's Multicultural Innovation Lab

Next

Cyclica Spins Out Startup, Perturba Therapeutics, From University Of Toronto